Loading organizations...
§ Private Profile · Heidelberg, Germany
Clinical-stage biotech develops therapeutics for Alzheimer's disease dementia, focused on agitation and aggression.
Exciva is a clinical-stage biotechnology company based in Heidelberg, Germany, that develops targeted therapeutics for neuropsychiatric conditions, specifically focusing on treating severe agitation and aggression in patients with Alzheimer's disease dementia. The organization's lead clinical program, EXV-802, combines validated compounds to target brain signaling without causing heavy sedation, and it recently received Fast Track Designation from the United States Food and Drug Administration. Currently advancing into Phase II clinical trials, the privately held firm secured €51 million in Series B funding in January 2026 to support its ongoing research and development efforts. This recent institutional financing round was co-led by Gimv and EQT Life Sciences, with additional participation from venture capital firms including Andera Partners, Fountain Healthcare Partners, and LifeArc Ventures. Exciva was founded in 2016 by Hans Moebius, Anton Bespalov, and Rao Vepachedu.
Exciva has raised $69.7M across 2 funding rounds.
Exciva has raised $69.7M in total across 2 funding rounds.
Exciva has raised $69.7M in total across 2 funding rounds.
Exciva's investors include Christoph Kocher, Philip Scheltens, Raphael WISNIEWSKI, Carma Fund, Aidan King, LBBW, LifeArc, Modi Ventures, Andera Partners, Karista, Wellington Partners, Cure8.
Exciva has raised $69.7M across 2 funding rounds. Most recently, it raised $59.7M Series B in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 20, 2026 | $59.7M Series B | Christoph Kocher, Philip Scheltens | Raphael Wisniewski, Carma Fund, Aidan King, LBBW, LifeArc, Modi Ventures | Announced |
| Oct 1, 2021 | $10M Series A | Andera Partners | Karista, Wellington Partners, Cure8, Stefanie Wojciech | Announced |
Exciva GmbH is a German biotechnology company developing therapies for neuropsychiatric symptoms in Alzheimer's disease, particularly agitation and aggression.[1][2] It pursues a targeted drug rescue program, repurposing existing compounds through rigorous clinical trials to deliver first-in-class treatments that improve patient quality of life, reduce caregiver burden, and transform dementia care.[1][2] The company serves Alzheimer's patients experiencing these symptoms, their caregivers, and families, addressing a major unmet need in neuropsychiatry.[1][2] With over $10 million in funding, including a €9 million Series A led by Andera Partners, Exciva has 6 employees and shows clinical momentum, advancing its lead candidate toward Phase II trials.[1][3]
Exciva GmbH was founded in 2015 (with some sources noting 2016) in Heidelberg, Germany, as a privately held biotech firm.[1][2][4] François Conquet serves as CEO, leading a team with deep expertise in central nervous system (CNS) research and pharmaceutical development from prior industry roles.[3] The idea emerged from identifying unmet needs in Alzheimer's behavioral symptoms, leveraging a drug rescue approach that combines compounds with proven safety and efficacy profiles.[1][3] Early traction came via support from Andera Partners since inception, culminating in the 2021 Series A round with LBBW Venture Capital and Cure 8, enabling Phase I completion and Phase II initiation.[3]
Exciva rides the wave of neuropsychiatry innovation in aging populations, targeting behavioral symptoms in Alzheimer's—a market with massive unmet needs amid rising dementia prevalence.[2][3] Timing aligns with advances in drug repurposing, which cuts costs and speeds timelines in biotech, especially post-pandemic emphasis on efficient CNS therapies.[1][3] Favorable forces include growing investor interest in Alzheimer's (e.g., Andera's medtech focus) and regulatory pushes for symptom-specific treatments.[3] Exciva influences the ecosystem by validating repurposed combos, potentially lowering barriers for similar CNS startups and shifting dementia care from symptom management to targeted relief.[2]
Exciva's path forward centers on Phase II trial success for its lead candidate, potentially yielding proof-of-concept data that de-risks partnerships or further funding.[3] Trends like AI-driven drug discovery and personalized neuropsychiatry will amplify its repurposing edge, while an aging global population sustains demand.[2] Its influence may grow through licensing deals or acquisitions by big pharma seeking Alzheimer's pipelines, solidifying Exciva as a key player in biotech's fight against dementia's hidden burdens—echoing its mission to restore patient dignity from day one.[2]